AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Fluticasone propionate is commonly prescribed as an inhaled corticosteroid (ICS) for the long-term management of asthma. It helps reduce airway inflammation, decrease bronchial hyperresponsiveness, and improve lung function. Regular use of fluticasone can reduce the frequency and severity of asthma symptoms, including wheezing, coughing, chest tightness, and shortness of breath.
Chronic Obstructive Pulmonary Disease (COPD): Fluticasone propionate, often combined with a long-acting beta-agonist (LABA) such as salmeterol, is used as a maintenance treatment for COPD, particularly in patients with frequent exacerbations. It helps reduce airway inflammation and symptoms associated with COPD, such as chronic cough, sputum production, and dyspnea (difficulty breathing).
Allergic Rhinitis: Fluticasone propionate nasal spray is indicated for the treatment of allergic rhinitis (hay fever) in adults and children. It helps relieve nasal congestion, sneezing, itching, and runny or stuffy nose associated with seasonal or perennial allergies.
Nasal Polyps: Fluticasone propionate nasal spray is also used for the management of nasal polyps, which are noncancerous growths that develop in the lining of the nasal passages. It helps reduce inflammation and shrink nasal polyps, thereby improving nasal airflow and reducing symptoms such as nasal congestion and loss of smell.
Sinusitis: Fluticasone propionate nasal spray may be prescribed as part of the treatment for acute or chronic sinusitis to reduce nasal inflammation and alleviate symptoms such as sinus pressure, facial pain, nasal discharge, and headache.
Eczema: Fluticasone propionate cream or ointment is sometimes used topically to manage inflammatory skin conditions such as eczema (atopic dermatitis). It helps relieve itching, redness, swelling, and discomfort associated with eczematous skin lesions by reducing inflammation and suppressing the immune response in the affected area.
Psoriasis: In some cases, fluticasone propionate cream or ointment may be prescribed for the treatment of mild to moderate psoriasis, a chronic skin condition characterized by thickened, red, and scaly patches on the skin. It helps reduce inflammation and control the symptoms of psoriasis, including itching and scaling.
Dermatitis: Fluticasone propionate cream or ointment may also be used to treat various forms of dermatitis, including allergic contact dermatitis, irritant contact dermatitis, and seborrheic dermatitis. It helps alleviate symptoms such as itching, redness, and inflammation associated with these inflammatory skin conditions.
Prevention of Nasal Polyps Recurrence: In patients who have undergone surgical removal of nasal polyps, fluticasone propionate nasal spray may be used as a maintenance therapy to prevent the recurrence of nasal polyps and reduce the need for additional surgical interventions.
Side Effects: Common side effects of fluticasone propionate may include nasal irritation, nosebleeds, sore throat, cough, headache, and hoarseness. Long-term use of high doses of fluticasone propionate may increase the risk of systemic side effects such as adrenal suppression, osteoporosis, cataracts, and glaucoma. It is important to use fluticasone propionate as directed by a healthcare professional and to monitor for potential side effects, especially with prolonged use.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 2.6 | 0.1 | 25 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 1 | 1.6 | -0.6 |
Allergies | 3 | 1.8 | 0.67 |
Allergy to milk products | 1.3 | 0.6 | 1.17 |
Alopecia (Hair Loss) | 0.8 | 0.8 | |
Alzheimer's disease | 1.3 | 2.6 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.7 | 0.43 |
Ankylosing spondylitis | 2.8 | 0.3 | 8.33 |
Anorexia Nervosa | 1.3 | -1.3 | |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0.8 | 0.6 | 0.33 |
Atherosclerosis | 0.8 | 0.9 | -0.13 |
Atrial fibrillation | 1.4 | 1.3 | 0.08 |
Autism | 4.3 | 4.3 | 0 |
Barrett esophagus cancer | 0.3 | 0.3 | |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.6 | 0.7 | -0.17 |
Brain Trauma | 0.8 | 0.6 | 0.33 |
Carcinoma | 1.9 | 1.5 | 0.27 |
Celiac Disease | 1.2 | 1.8 | -0.5 |
Cerebral Palsy | 1 | 0.8 | 0.25 |
Chronic Fatigue Syndrome | 2.1 | 2.2 | -0.05 |
Chronic Kidney Disease | 0.6 | 0.9 | -0.5 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.4 | -0.33 |
Chronic Urticaria (Hives) | 1.6 | 0.4 | 3 |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.5 | 0.8 |
Colorectal Cancer | 1.9 | 0.8 | 1.37 |
Constipation | 0.6 | 0.5 | 0.2 |
Coronary artery disease | 0.5 | 0.5 | 0 |
COVID-19 | 6.4 | 5.6 | 0.14 |
Crohn's Disease | 3.6 | 2 | 0.8 |
cystic fibrosis | 0.9 | 0.9 | 0 |
deep vein thrombosis | 0.9 | 0.3 | 2 |
Depression | 4.3 | 4.2 | 0.02 |
Dermatomyositis | 0.3 | -0.3 | |
Eczema | 0.6 | 0.7 | -0.17 |
Endometriosis | 2 | 0.4 | 4 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 1.5 | 0.8 | 0.88 |
Fibromyalgia | 1.4 | 1.6 | -0.14 |
Functional constipation / chronic idiopathic constipation | 2.9 | 2.3 | 0.26 |
gallstone disease (gsd) | 1.4 | 0.6 | 1.33 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.4 | -0.33 |
Generalized anxiety disorder | 1.1 | 1.5 | -0.36 |
giant cell arteritis | 0.4 | -0.4 | |
Gout | 0.1 | -0.1 | |
Graves' disease | 1 | 1.1 | -0.1 |
Halitosis | 0.5 | 0.5 | |
Hashimoto's thyroiditis | 1.3 | 0.6 | 1.17 |
Hidradenitis Suppurativa | 0.3 | -0.3 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.6 | 0.2 | 12 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.3 | 0.8 | -1.67 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.4 | 1 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.4 | 2.9 | -1.07 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 1.7 | -1.7 | |
Inflammatory Bowel Disease | 2.3 | 3.5 | -0.52 |
Insomnia | 0.4 | 0.6 | -0.5 |
Intelligence | 0.5 | 0.4 | 0.25 |
Intracranial aneurysms | 0.5 | 0.4 | 0.25 |
Irritable Bowel Syndrome | 3.1 | 1.7 | 0.82 |
Liver Cirrhosis | 2.4 | 1.9 | 0.26 |
Long COVID | 3 | 4.6 | -0.53 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.8 | 0.4 | 1 |
ME/CFS with IBS | 0.4 | 1.5 | -2.75 |
ME/CFS without IBS | 0.7 | 1.2 | -0.71 |
Menopause | 1.8 | 1.8 | |
Metabolic Syndrome | 4.7 | 4 | 0.18 |
Mood Disorders | 6.2 | 4.2 | 0.48 |
multiple chemical sensitivity [MCS] | 0.3 | 0.2 | 0.5 |
Multiple Sclerosis | 1.4 | 2.4 | -0.71 |
Multiple system atrophy (MSA) | 0.6 | 0.5 | 0.2 |
Neuropathy (all types) | 0.2 | 0.3 | -0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 2.7 | -0.35 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 5.1 | 1.6 | 2.19 |
obsessive-compulsive disorder | 2.7 | 1.6 | 0.69 |
Osteoarthritis | 1.3 | 0 | 0 |
Osteoporosis | 1.3 | 0.4 | 2.25 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 1.5 | 1.2 | 0.25 |
Polycystic ovary syndrome | 1.2 | 1.2 | 0 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.4 | 0 |
Premenstrual dysphoric disorder | 1 | 1 | |
primary biliary cholangitis | 0.2 | 0.4 | -1 |
Psoriasis | 3.1 | 1.1 | 1.82 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.5 | 2.4 | 0.46 |
Rosacea | 0.4 | 0.7 | -0.75 |
Schizophrenia | 4.4 | 1.3 | 2.38 |
scoliosis | 0.1 | 0.1 | 0 |
Sjögren syndrome | 1.8 | 1.9 | -0.06 |
Sleep Apnea | 0.6 | 0.9 | -0.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.4 | 0.5 |
Stress / posttraumatic stress disorder | 2.1 | 1.5 | 0.4 |
Systemic Lupus Erythematosus | 1.2 | 1 | 0.2 |
Tic Disorder | 0.1 | 1.4 | -13 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.6 | 1.6 | 0 |
Type 2 Diabetes | 4.3 | 2.6 | 0.65 |
Ulcerative colitis | 2.3 | 2.4 | -0.04 |
Unhealthy Ageing | 0.9 | 0.9 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.